Revumenib Earns FDA Priority Review in R/R KMT2Ar Acute Leukemia
Revumenib, a first-in-class Menin inhibitor, was granted priority review from the FDA for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.
Revumenib, a first-in-class Menin inhibitor, was granted priority review from the FDA for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.
US cancer survivors are more likely than the general population to have a mobility or self-care disability, a large study suggests.
Douglas B. Johnson, MD, MSCI, of Vanderbilt-Ingram Cancer Center, discusses updated guidelines on the use of neoadjuvant therapy, as well as first- and later-line systemic…
Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.
VJHemOnc is excited to share an exclusive case study exploring the current approach to the diagnosis and classification of follicular lymphoma.
Researchers investigated the risk of T-cell malignant neoplasms and any second primary malignant neoplasms in patients receiving CAR T-cell therapy for hematologic malignancies.
Anne P. O’Dea, MD, presents the case of a 49-year-old woman with HR+/HER2- metastatic breast cancer and offers initial impressions on the patient’s risk and…
The first in ASTCT’s new CAR T Webinar Series aired on June 9, 2021 with our speaker, Dr. Marcela Maus, and our moderator, Dr. Armin…
Simulation-based education can improve health care professionals’ understanding and confidence regarding the treatment of patients with CAR T-cell therapy.
Are desmoid tumors benign or malignant? How are they diagnosed and treated? And, are they associated with any genetic mutations? Sarcoma specialist Shreyaskumar Patel, M.D.,…
The third prespecified interim analysis of overall survival in the phase III KEYNOTE-564 trial has shown a significant benefit with adjuvant pembrolizumab vs placebo in…